Furthermore, clinical trials with RHAMM peptide vaccination have demonstrated clinical and immunological responses in patients with acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and myelodysplastic syndrome (MDS) [39,40,41]. The gene discussed is HMMR; the disease is B-cell chronic lymphocytic leukemia.